Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
1. FDC obicetrapib plus ezetimibe significantly decreased LDL cholesterol levels by 48.6% compared to placebo. 2. Serious adverse events were ...
Tag: dyslipidemia
Dyslipidemia contributes to greater incidence of diabetic kidney disease
The ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol is associated with diabetic kidney disease: A cross-sectional study 1. ...
Beneficial effects of hydroxychloroquine on blood lipids and glycated haemoglobin
1. Hydroxychloroquine significantly improves the lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus Evidence Rating Level: 1 ...
Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving radiotherapy
1. In a cohort of individuals with invasive ductal carcinoma (IDC) that underwent breast-conserving surgery (BCS) and adjuvant breast radiotherapy, ...
Arrowhead Pharmaceuticals: RNA interference Medication Plozasiran Lowers Triglycerides in Dyslipidemia
Patients with familial chylomicronemia syndrome (FCS) treated with plozasiran demonstrated a maximum reduction of 98% in triglyceride levels at month ...
Hyperlipidemia may be associated with greater risk of stenosing tenosynovitis
1. In a large Taiwanese cohort, it was found that patients with hyperlipidemia had higher risk of developing stenosing tenosynovitis, ...
Risk of myopathy and myalgia among statin users may be small and clinically insignificant
1. 27.1% of patient in the statin group reported muscle pain and weakness compared to 26.6% in the control groups. ...
Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy
1. 3-year composite outcome of stroke and cardiovascular disease was comparable between both groups (9.1% combination vs. 9.9% monotherapy). 2. ...
Once-a-week cagrilintide is effective for weight management in overweight and obese patients
1. By week 26, cagrilintide resulted in significantly increased weight reduction compared to liraglutide and placebo. 2. Gastrointestinal adverse events, ...
Combination-drug therapy and earlier detection recommended to improve outcomes in heterozygous familial hypercholesterolemia
1. A significantly greater proportion of patients receiving 2-3 lipid lowering medications achieved LDL-cholesterol targets compared to those receiving monotherapy. ...